Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06204315

Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery

To learn about the safety of a procedure called cord dose escalated spine stereotactic radiosurgery (CDE-SSRS) in patients with MESCC.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location status: Recruiting

Location contact

Amol Ghia, MD

CONTACT

[email protected]

832-628-7357

Amol Ghia, MD

PRINCIPAL_INVESTIGATOR

About this study

Primary Objectives The primary protocol objectives are to establish the safety of CDE-SSRS alone in participants with MESCC. Specifically, we aim to maintain an RM risk no greater than 1%. RM will be defined as non-functional paresis per the McCormick score (i.e., Grade D).

Secondary Objectives Secondary objectives include pain control as measured by the Brief Pain Inventory, quality of life as measured by the EQ-5D, symptom burden as measured by the MDASI-SP, overall survival, toxicity, ambulatory rate and cost-effectiveness. LC will be defined radiographically with serial MRI scans by the study radiologist per SPINO criteria.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Greater than or equal to 18 years old
  • Radiographically documented spinal metastasis on spine MRI within 4 weeks of registration
  • Proximity of spinal metastasis to spinal cord or cauda equina which precludes achieving a GTV Dmin of at least 14 Gy per the PI
  • All participants must be able to receive single fraction SSRS at the site of interest with 0.01 cc of the spinal cord receiving 14-16 Gy and/or 0.01 cc of the cauda equina receiving 18-20 Gy. The goal of treatment is to select the minimal dose to the organ at risk which will achieve a GTV Dmin of 14 Gy at the treating physician's discretion.
  • Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session
  • All participants must be able to receive a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 Gy
  • All participants must have a vertebral level site of interest from C1 to S2
  • Signed informed consent
  • Diagnosis of cancer excluding ultra-radiosensitive histologies (see 4.2)
  • Motor strength ≥ 4 out of 5 in extremity or extremities affected by the level of cord compression
  • ECOG ≤ 2

Exclusion criteria

  • Participants with ultra-radiosensitive histologies (lymphoma, multiple myeloma/plasmacytoma)
  • Prior history of radiation at the spinal site of interest
  • Inability to lie supine comfortably for ≥ 60 minutes
  • Progressive neurological deficits due to compression
  • Inability of obtain an MRI
  • Inability or refusal to undergo an MR simulation
  • No eligible for single fraction SSRS for any reason
  • Participants who are pregnant

Treatment and study plan

Stereotactic Radiosurgery

Radiation

Given by RTx

Other names: CDE-SSRS

Primary outcomes

  1. Safety and adverse events (AEs)

    Time frame: Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Study contacts

Contact information is provided by the study sponsor or research team.

Amol Ghia, MD

CONTACT

[email protected]

(832) 628-7357

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Collaborators

  • Brainlab AG

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2029
First posted
Jan 12, 2024
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.